samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As we head towards the cooler weather, shorter days and bombardment of Autumn conferences, the annual BIO 2001 meeting in San Diego in June may seem like a long time ago. However, the memory of a marathon BIO with over 13,000 participants from all over the world, 700 exhibitors, 230 presenting companies and 15 conference tracks will probably stay with most of us for a long time to come. The sheer scale of the meeting and the buzz in the conference halls (and queues) reflected just how much the industry continues to grow and evolve in the post-2000 financing bonanza. Though times are now much tougher - with talk of recession on either side of the Atlantic, concern over the lack of leadership at the FDA, safety concerns, product withdrawals and manufacturing capacity problems (not forgetting the President Bush/stemcell/federal funding debate) - its not all doom and gloom for biotech. Many companies raised significant funds in the US and Europe last year and are now actively employing them in bringing products through development and negotiating higher value alliance deals with larger pharma partners. The pace of advance in science is also compelling and the blend of genomics, proteomics, informaticsand high throughput technologies is beginning to mature into new product development strategies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Myonex Opens New Global Headquarters

Myonex, a leading global clinical trial supply company, marked the opening of its new global headquarters and US operational facility with a ribbon-cutting ceremony on the company’s 14-acre campus.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement